Skip to main content

Advertisement

Table 2 Demographic and clinical characteristics of participants at baseline in the multiple dose study

From: Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

Parameters (Unit) Statistics/Category Multiple Dose Study
   Placebo Ferroquine
   (N = 7) 400 mg (N = 6) 600 mg (N = 6) 800 mg (N = 6) 1000 mg (N = 1)
Age (years) Mean (SD) 23.6 (5.3) 30.2 (6.2) 26.2 (6.3) 24.5 (5.8) NA
  Min - Max 18 - 33 25 - 40 18 - 35 19 - 32  
Height (cm) Mean (SD) 168.6 (6.5) 167.5 (5.8) 166.5 (10.5) 170.8 (9.9) NA
  Min - Max 160 - 178 158 - 173 150 - 181 155 - 184  
Weight (kg) Mean (SD) 63.0 (2.6) 64.8 (8.3) 59.8 (10.1) 61.3 (5.0) NA
  Min - Max 59 - 66 55 - 75 50 - 74 56 - 70  
BMI (kg/m 2 ) Mean (SD) 22.24 (1.61) 23.03 (1.74) 21.48 (1.97) 21.05 (1.19) NA
  Min - Max 20.5 - 25.0 21.3 - 25.3 19.2 - 24.5 19.8 - 23.3  
BSA (m 2 ) Mean (SD) 1.67 (0.09) 1.73 (0.13) 1.66 (0.19) 1.72 (0.13) NA
  Min - Max 1.6 - 1.8 1.5 - 1.9 1.4 - 1.9 1.5 - 1.9  
HR (bpm) Mean (SD) 53.8 (6.9) 59.2 (7.8) 55.6 (3.7) 52.9 (1.2) NA
  Min - Max 48 - 63 52 - 72 51 - 60 48 - 62  
QTc B (ms) Mean (SD) 366.6 (11) 380.7 (15.7) 359.0 (21.8) 373.8 (24) NA
  Min - Max 358 - 384 367 - 409 150 - 181 340 - 406  
QTc F (ms) Mean (SD) 373,9 (6.3) 382.0 (11.7) 362.8 (22.5) 381.2 (24.5) NA
  Min - Max 368 - 382 372 - 403 335 - 404 340 - 399  
  1. NOTE: BMI: Body Mass Index; BSA: Body Surface Area; HR: Heart Rate; QTc (Bazett Fridericia); N: Count of patients; SD: standard deviation; Min: minimum; Max: maximum